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Abstract 16 
Adiponectin is a salutary adipokine and hypoadiponectinemia is implicated in the aetiology 17 
of obesity-related inflammation and cardiometabolic disease making therapeutic strategies to 18 
increase adiponectin attractive.  Emerging evidence, predominantly from preclinical studies, 19 
suggests induction of heme-oxygenase-1 (HO-1) increases adiponectin production and 20 
reduces inflammatory tone.  Here, we aimed to test whether induction of HO-1 enhanced 21 
adiponectin production from mature adipocytes.  Treatment of human adipocytes with cobalt 22 
protoporphyrin (CoPP) or hemin for 24-48 h increased HO-1 expression and activity without 23 
affecting adiponectin expression and secretion.  Treatment of adipocytes with TNFα reduced 24 
adiponectin secretion and increased expression and secretion of additional pro-inflammatory 25 
cytokines, IL-6 and MCP-1, as well as expression of sXBP-1, a marker of ER stress.  HO-1 26 
induction failed to reverse these effects. These results demonstrate that induction of HO-1 27 
does not directly enhance adiponectin production or ameliorate the pro-inflammatory effects 28 
of TNFα and argue against a direct HO-1 – adiponectin axis. 29 
 30 
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1. Introduction 32 
Adiponectin is an adipocyte-derived hormone that regulates glucose and lipid metabolism via 33 
direct and indirect mechanisms and has beneficial anti-inflammatory, anti-diabetic, anti-34 
atherogenic and cardioprotective properties (Esmaili et al., 2014; Hickman and Whitehead, 35 
2012; Parker-Duffen and Walsh, 2014; Tao et al., 2014).  Paradoxically, and in contrast to 36 
most other adipocyte-derived hormones or “adipokines”, circulating adiponectin levels are 37 
reduced in obesity (Ye and Scherer, 2013).  Although the precise mechanisms for this 38 
reduction are unclear metabolic, oxidative and or inflammatory stress are all implicated. The 39 
structural complexity of adiponectin appears to be an additional factor that makes it 40 
particularly sensitive to such cellular stresses (Hickman and Whitehead, 2012).  Briefly, 41 
adiponectin is synthesised as a monomer that undergoes multimerisation to form higher order 42 
species via a coordinated process that involves a number of post-translational modifications.  43 
Efficient multimerisation to trimer, hexamer and high molecular weight (HMW) multimers is 44 
a prerequisite for efficient secretion.  Moreover, functional studies suggest HMW adiponectin 45 
is the most metabolically active form (Simpson and Whitehead, 2010; Wang et al., 2008). 46 
Evidence suggests that hypoadiponectinemia contributes to the aetiology of obesity-related 47 
cardiometabolic diseases and that this typically reflects a selective decrease in the circulating 48 
levels of HMW adiponectin (Hickman and Whitehead, 2012).  Consistent with this, 49 
numerous pre-clinical and clinical studies demonstrate that reversal of hypoadiponectinemia 50 
improves a range of cardiometabolic parameters thereby establishing the adiponectin system 51 
as an attractive therapeutic target (Lim et al., 2014; Pajvani et al., 2004). 52 
Heme oxygenase-1 (HO-1), which is sometimes called heat shock protein 32 (Hsp32), is an 53 
inducible protein that serves as a rate-limiting enzyme catalysing the oxidative degradation of 54 
heme to carbon monoxide (CO),  iron and biliverdin, which is subsequently converted to 55 
bilirubin (Wegiel et al., 2014).  Each of the products of HO-1 activity modulates various 56 
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aspects of cellular function and homeostasis (Wegiel et al., 2014) prompting some to propose 57 
HO-1 as a dual purpose “sensor/effector” that both senses and responds to oxidative, 58 
inflammatory and metabolic stress (Motterlini and Foresti, 2014).  Consistent with this most, 59 
but not all (Jais et al., 2014), investigators promote the induction of HO-1 as an attractive 60 
therapeutic strategy to ameliorate the pathophysiology of a range of human diseases including 61 
metabolic disorders such as insulin resistance, type 2 diabetes and obesity (Hosick and Stec, 62 
2012; Son et al., 2013).  As such, considerable efforts are being made to identify efficacious 63 
approaches to induce HO-1 in man (Bharucha et al., 2010; Li et al., 2007; Motterlini and 64 
Foresti, 2014). 65 
Accumulating evidence has led to the suggestion that HO-1 may mediate at least some of its 66 
beneficial effects by increasing circulating adiponectin levels through what has been termed 67 
the “HO-1 – adiponectin axis” (Cao et al., 2012a; Cao et al., 2011; Issan et al., 2012; Kim et 68 
al., 2010; Li et al., 2008; Ndisang and Chibbar, 2014; Ndisang et al., 2014; Ndisang and 69 
Jadhav, 2014; Salamone and Li Volti, 2010; Seow et al., 2011; Vanella et al., 2012).  For 70 
example, chronic administration of obese mice with the HO-1 inducer cobalt protoporphyrin 71 
(CoPP) was reported to increase HO-1 protein, prevent weight gain and decrease fat content 72 
(in the absence of any change in food intake), reduce circulating inflammatory cytokines 73 
(including TNFα and IL-6) and increase circulating adiponectin levels (Li et al., 2008).  74 
Consistent with these changes insulin sensitivity and glucose tolerance were improved in this 75 
pre-clinical model thereby providing further evidence of the potential therapeutic benefits of 76 
HO-1 induction.  Complementary ex vivo studies on isolated bone marrow-derived 77 
mesenchymal stem cells demonstrated reduced adipogenesis and increased adiponectin 78 
production upon chronic CoPP treatment in support of a regulatory HO-1 – adiponectin axis 79 
(Li et al., 2008). 80 
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In spite of the findings detailed above, which typically describe the effects of chronic 81 
induction of HO-1 on adiponectin levels in vivo or in vitro, to the best of our knowledge no 82 
studies have examined whether induction of HO-1 has a direct effect on adiponectin 83 
production.  Thus, the purpose of the present work was to test the hypothesis that acute 84 
induction of HO-1 in mature adipocytes would increase the production of adiponectin, 85 
particularly the more metabolically active HMW multimers.  Surprisingly, we found no 86 
evidence to support a direct effect of HO-1 on adiponectin production (total or HMW), or 87 
improvements in markers of cellular stress, in human adipocytes in a variety of experimental 88 
scenarios.  These results argue against a direct HO-1 – adiponectin axis. 89 
 90 
2. Material and Methods 91 
2.1. Reagents and antibodies 92 
General reagents were obtained from Sigma-Aldrich (Victoria, Australia) and cell culture 93 
reagents were obtained from Invitrogen (Victoria, Australia) unless otherwise stated. 94 
2.2. SGBS cell culture, differentiation and treatment 95 
Human SGBS preadipocytes, a gift from Martin Wabitsch (University of Ulm, Ulm, 96 
Germany) (Wabitsch et al., 2001), were maintained and differentiated in the absence of serum 97 
as described (Newell et al., 2006). Fully differentiated cells (day 14) were treated with 98 
increasing concentrations of CoPP (0, 50, 100, and 150 nM) or Hemin (0, 1, 5 µM), or 99 
vehicle, in the presence or absence of TNFα (50 ng/mL). Cells and conditioned media were 100 
harvested after 24 h or 48 h (following a media change at 24 h for the latter).  For 101 
experiments performed in the presence of serum, cells were differentiated and maintained in 102 
media containing 10% FBS and treated with increasing concentrations of CoPP (0, 5, 10 µM) 103 
in the presence or absence of TNFα (50 ng/mL) on day 14. Cells and conditioned media were 104 
harvested after 24 h. 105 
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2.3. Isolation, culture, differentiation and treatment of Primary Human Preadipocytes 106 
Primary human preadipocytes (phPAs) were isolated from subcutaneous adipose tissue from 107 
two subjects (both female, age 25 & 39 years, BMI 24.1 & 23.3, metabolically healthy - no 108 
insulin resistance, diabetes or cardiovascular diseases) and cultured independently as 109 
described previously (Newell et al., 2006). The procedure was approved by the Research 110 
Ethics Committees of the University of Queensland, the Princess Alexandra Hospital, and the 111 
Mater Adults Hospital. Both patients had given their written informed consent.  Treatments 112 
were performed in fully differentiated cells (day 21) as described above (section 2.2). 113 
2.4. Measurement of gene expression by qRT-PCR. 114 
Gene expression was measured by qRT-PCR and standardized against the expression of 115 
cyclophilin essentially as previously described (Newell et al., 2006).  Briefly, total RNA was 116 
extracted using Trizol or RNA Mini Kit (Ambion Life Technologies, Victoria, Australia) 117 
according to the manufacturer‟s instructions. cDNA was synthesized from 1 μg total RNA 118 
using a cDNA synthesis kit (Bioline, NSW, Australia) and RT-PCR was performed using the 119 
SYBR Hi-ROX kit (Bioline) on a 7900HT Fast Real-time PCR system (Ambion Life 120 
Technologies).  Primer sequences are available on request. 121 
2.5. Determination of HO-1, Adiponectin and IL-6 protein 122 
Cellular HO-1 was quantitated in whole cell lysates (in 0.05-0.25 µg protein) using a HO-1 123 
ELISA (Life Sciences, Florida, USA).  Secreted total and HMW adiponectin was quantitated 124 
using an Adiponectin ELISA Kit (ALPCO, New Hampshire, USA and R&D system, 125 
Minnesota, USA).  Absolute secreted total and HMW adiponectin levels are presented for 126 
each set of experiments in the Figure Legend as mean ± SEM (range: lowest - highest) ng/ml.  127 
Data presented in graphs are normalised to values from the control cells (no treatments) 128 
which were arbitrarily set at 1. Secreted IL-6 was measured in conditioned media (at a 1 in 2 129 
dilution) using an IL-6 ELISA (R&D system, Minnesota, USA).   130 
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2.6. SDS-PAGE/Western blot of ferritin 131 
SDS-PAGE and Western blotting of cleared whole cell lysates (centrifuged at 2,000 x g for 132 
10 min) was performed using standard approaches (Richards et al., 2006).  Ferritin antibody 133 
was from MP Biomedicals, (Aurora, Ohio, USA - Catalogue # 65077 - used at 1:2,000) and 134 
was followed by an Alexa-800 conjugated secondary anti-rabbit antibody (Molecular Probes, 135 
VIC, Australia – used at 1:20,000) and scanned using the LI-COR Odyseey Infrared Imaging 136 
System. 137 
2.7. Statistical analysis 138 
Data are presented as mean ± SEM. One-way ANOVA followed by Tukeys was used to test 139 
for a significant effect of CoPP or hemin in cells incubated without TNFα or independently in 140 
cells treated with TNFα. When there was no effect of CoPP or hemin a Student t-test 141 
(unpaired) was used to test for a significant effect of TNFα.  Differences were considered 142 
statistically significant at p<0.05. Statistical analyses were performed using GraphPad Prism 143 
5.0. 144 
 145 
3. Results 146 
3.1. Acute CoPP treatment induces HO-1 in a dose-dependent manner in SGBS adipocytes 147 
To investigate whether induction of HO-1 has a direct effect on adiponectin expression or 148 
secretion we first performed a series of dose response studies in mature (day 14) human 149 
SGBS adipocytes to identify optimal CoPP concentrations.  We established that treatment 150 
with CoPP for 24-48 h at concentrations from 50-150 nM was sufficient to promote robust 151 
(10-50 fold) induction of HO-1 mRNA and protein in control cells as well as cells treated 152 
with the pro-inflammatory cytokine TNFα (Fig 1A-D), which compromises adiponectin 153 
expression and secretion (Rose et al., 2010).  Treatment of SGBS adipocytes with higher 154 
concentrations of CoPP (from 600 nM to 10 µM) failed to promote any further significant 155 
 Yang et al, Evidence against a direct HO-1 – adiponectin axis 
 
8 
 
increase in HO-1 levels, but induced signs of toxicity at concentrations greater than 2 µM 156 
(data not shown).  Thus, subsequent experiments were performed using CoPP in the 50-150 157 
nM range. 158 
3.2. Acute CoPP treatment has no effect on adiponectin production in SGBS adipocytes 159 
Having established that treatment with CoPP for 24-48 h was sufficient to induce HO-1, in 160 
the absence or presence of TNFα, we then examined the effects of CoPP treatment on 161 
adiponectin expression and secretion.  There was no significant effect of CoPP treatment on 162 
adiponectin mRNA levels after 24 or 48 h treatment in either the control or the TNFα treated 163 
cells (Fig 2A & B).  TNFα treatment significantly reduced adiponectin mRNA levels to 164 
around 50% of those in control cells.  Measurement of secreted total and HMW adiponectin 165 
into the conditioned media was performed by ELISA.  There was no significant effect of 166 
CoPP treatment on total or HMW adiponectin secretion after 24 or 48 h treatment in either 167 
the control or TNFα treated cells (Fig 2C-F).  TNFα treatment significantly reduced total and 168 
HMW adiponectin secretion by around 40% and 80% at 24 and 48 h respectively.  These 169 
results indicate that CoPP has no effect on adiponectin mRNA expression or protein secretion 170 
in healthy SGBS adipocytes or in TNFα-treated adipocytes where adiponectin expression and 171 
secretion is significantly compromised. 172 
3.3. Acute CoPP treatment has no effect on pro-inflammatory cytokine production in SGBS adipocytes  173 
Induction of HO-1 has been shown to reduce the circulating levels of pro-inflammatory 174 
cytokines (Burgess et al., 2010; Vanella et al., 2013).  To investigate whether HO-1 induction 175 
mediated such beneficial effects in SGBS adipocytes we examined the effects of CoPP 176 
treatment on TNFα-induced IL-6, TNFα and MCP-1 expression and IL-6 secretion.  TNFα 177 
treatment for 24-48 h resulted in a significant increase in IL-6 mRNA and secretion (Fig 3A-178 
D) as well as TNFα and MCP-1 expression (Fig 3E-H). However, treatment with CoPP failed 179 
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to ameliorate the pro-inflammatory effects of TNFα. These results indicate that CoPP has no 180 
effect on pro-inflammatory cytokine production in healthy SGBS adipocytes or in TNFα-181 
treated adipocytes where pro-inflammatory cytokine production is significantly increased. 182 
3.4. Acute CoPP treatment has no effect on ER stress  183 
We next went on to investigate the effects of HO-1 induction and TNFα-treatment on 184 
markers of ER stress.  TNFα treatment resulted in a significant, two-fold increase in sXBP-1 185 
expression and this was unaffected by HO-1 induction (Fig 4A & B). Treatment with CoPP 186 
or TNFα had no significant effect on GRP78 (BiP) or CHOP expression (Fig 4C-F).  187 
3.5. Addition of exogenous substrate does not promote a response to HO-1 induction in SGBS 188 
adipocytes 189 
The above studies were performed in SGBS adipocytes differentiated and maintained in 190 
defined medium without serum in accordance with our standard experimental approaches 191 
(Hutley et al., 2011; Newell et al., 2006; Widberg et al., 2009).  Thus, it remained plausible 192 
that the lack of any discernible effect of HO-1 induction on adiponectin or pro-inflammatory 193 
cytokine production may reflect limited substrate availability (Sheftel et al., 2007).  To 194 
investigate whether this was the case we employed complementary approaches.  First, we 195 
performed similar experiments in cells treated with hemin, which serves as both inducer and 196 
substrate of HO-1 (Shan et al., 2006; Sheftel et al., 2007).  Treatment with hemin at 197 
concentrations from 1-5 μM for 48 h was necessary and sufficient to promote a 5-10 fold 198 
induction in cellular HO-1 protein (Fig 5A & data not shown).  However, such induction of 199 
HO-1 had no effect on adiponectin or IL-6 secretion in control or TNFα treated cells (Fig 5B 200 
& C).  Second, we determined the effects of HO-1 induction with hemin or CoPP on ferritin 201 
protein levels, which serves as an indirect marker of HO-1 activity (Sheftel et al., 2007).  As 202 
expected, induction of HO-1 with either hemin or CoPP markedly induced the levels of 203 
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ferritin protein (Fig 5D & E).  Third, we performed experiments in cells that were 204 
differentiated and subsequently treated with CoPP in the presence of 10% fetal bovine serum.  205 
Treatment with CoPP induced HO-1 (Fig 6A), although higher concentrations (5-10 µM) 206 
were required to induce HO-1 to the levels observed following treatment in the absence of 207 
serum, probably reflecting sequestration of CoPP via binding to serum factors.  TNFα 208 
treatment significantly reduced adiponectin production and increased IL-6 production, albeit 209 
to a lesser extent than was observed  in the absence of serum.  There was no significant effect 210 
of CoPP on adiponectin or IL-6 production in either the control or TNFα-treated cells (Fig 211 
6B-E).  Collectively, these data indicate that induction of HO-1, even in the presence of 212 
exogenous substrates, does not affect adiponectin production nor reduce the pro-213 
inflammatory effects of TNFα in mature SGBS adipocytes. 214 
3.6. Acute CoPP treatment induces HO-1 in primary human adipocytes but does not affect 215 
adiponectin and IL-6 production 216 
Next, to extend our observations from the SGBS adipocytes we performed similar 217 
experiments in primary human adipocytes treated in the absence and presence of serum.  218 
Treatment with CoPP for 24 h promoted a dose-dependent increase in HO-1 mRNA and this 219 
was comparable in the absence or presence of TNFα (Fig 7A & B).  Treatment with TNFα 220 
significantly reduced adiponectin production and increased IL-6 production (Fig 7C-J).  221 
Induction of HO-1 with CoPP had no impact on adiponectin or IL-6 production in control or 222 
TNFα treated cells in either the absence or presence of serum (Fig 7C-J).  These results are 223 
consistent with those from the SGBS adipocytes and argue against the existence of a direct 224 
HO-1 – adiponectin axis and any major anti-inflammatory role for HO-1 in the context of 225 
mature human adipocytes. 226 
 227 
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4. Discussion 228 
In the current investigation we aimed to determine whether induction of HO-1 has a direct 229 
effect on adiponectin production from mature adipocytes, and thereby contribute to the 230 
purported HO-1 – adiponectin axis.  We could find no evidence to support a direct beneficial 231 
effect of HO-1 induction on adiponectin expression or secretion in healthy or TNFα-treated 232 
SGBS or primary human adipocytes.  Indeed, despite robust induction of HO-1 mRNA, 233 
protein and activity, we observed no beneficial effects of HO-1 induction on these parameters 234 
or on TNFα-induced ER stress or pro-inflammatory adipocytokine production. 235 
Numerous reports have described an association between pharmacological induction of HO-1 236 
and increased circulating levels of the beneficial adipokine adiponectin, in in vivo studies in 237 
rodents (Cao et al., 2012a; Cao et al., 2011; Cao et al., 2012c; Hinds et al., 2014; Kim et al., 238 
2008; L'Abbate et al., 2007; Li et al., 2008; Ndisang and Jadhav, 2014; Vanella et al., 2012; 239 
Vanella et al., 2013), and in vitro studies, showing increased adiponectin secretion from 240 
adipocytes (Kim et al., 2008; Vanella et al., 2013).  These observations stimulated the 241 
proposal of a HO-1 – adiponectin axis (Cao et al., 2012a; Cao et al., 2011; Issan et al., 2012; 242 
Kim et al., 2010; Li et al., 2008; Ndisang and Chibbar, 2014; Ndisang et al., 2014; Ndisang 243 
and Jadhav, 2014; Salamone and Li Volti, 2010; Seow et al., 2011; Vanella et al., 2012) 244 
which could underpin, at least in part, the favourable effects of HO-1 induction reported in 245 
most pre-clinical models of obesity and related cardiometabolic disorders.  Thus, we reasoned 246 
information affording a greater understanding of the cellular and molecular framework of the 247 
HO-1 – adiponectin axis would help to identify, validate and progress development of 248 
efficacious therapeutic approaches.   249 
To this end, we performed a series of experiments on mature SGBS and primary human 250 
adipocytes differentiated in vitro.  Treatments were limited to mature adipocytes in order to 251 
reduce the potential for confounding effects on the differentiation process, as has been 252 
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reported by others (Kim et al., 2008; Peterson et al., 2009; Vanella et al., 2010; Vanella et al., 253 
2013), and incubation periods were limited to 24-48 h to reduce the likelihood of secondary 254 
effects.  As expected, treatment with two widely used inducers of HO-1, CoPP and Hemin, 255 
resulted in increased HO-1 expression at both the mRNA and protein level.  A concomitant 256 
increase in HO-1 activity was demonstrated by increased ferritin protein, the levels of which 257 
are elevated in response to the increase in cellular iron levels (Sheftel et al., 2007).   Perhaps 258 
surprisingly then, we found no evidence of any effect on adiponectin expression, 259 
multimerisation or secretion.  This was the case in healthy control adipocytes as well as 260 
adipocytes co-treated with TNFα, a pro-inflammatory cytokine implicated in the aetiology of 261 
obesity-related cardiometabolic dysfunction, known to promote insulin resistance and 262 
compromise adiponectin production from adipocytes (Rose et al., 2010).  Furthermore, there 263 
was no indication of any impact of HO-1 induction on other markers of cellular stress 264 
stimulated by TNFα, most notably the induction of other pro-inflammatory cytokines 265 
including IL-6 and MCP-1 as well as induction of TNFα itself.   266 
The above findings indicate that acute induction of HO-1 has no direct effect on adiponectin, 267 
or adipocytokine, production at the level of the mature adipocyte and instead support a model 268 
where the association between HO-1 induction and increased circulating adiponectin levels 269 
most likely represents a chronic or indirect effect.  One possibility is that chronic induction of 270 
HO-1 may increase adiponectin via altering differentiation of preadipocytes.  Consistent with 271 
this, in vitro studies showed that chronic induction of HO-1, via CoPP administration 272 
throughout differentiation, promoted increased adiponectin secretion, albeit in the context of 273 
reduced adipogenesis (Kim et al., 2008; Vanella et al., 2013).  Whilst it seems somewhat 274 
paradoxical that inhibition of adipogenesis would result in increased adiponectin secretion, 275 
given the dose-dependent effects of chronic CoPP treatment (Vanella et al., 2013) and the 276 
finding that adiponectin secretion is highest in „immature‟ adipocytes (Luo et al., 2012) it 277 
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remains possible that there is an „optimal window‟ for adiponectin secretion that was 278 
somewhat serendipitously established in these investigations (Kim et al., 2008; Vanella et al., 279 
2013).  In vivo findings showing altered adipose tissue architecture consistent with reduced 280 
adipocyte hypertrophy and increased adipocyte number appear to support such a model, 281 
however increased adipogenesis is intrinsically required in such a situation (Luo et al., 2012).  282 
Further investigations are required to establish whether this is the case or whether the 283 
decrease in adipocyte hypertrophy simply reflects a decrease in body weight (see below).   284 
Another possibility is that induction of HO-1 may mediate adiponectin production from 285 
adipocytes indirectly via its effects on other cell types.  For example, a recent report 286 
demonstrates that acute (24 h) induction of HO-1 via hemin increases adiponectin expression 287 
from 3T3-L1 adipocytes co-cultured with Raw264.7 macrophages (Tu et al., 2014).  The 288 
inflammatory tone of the co-cultured 3T3-L1 adipocytes and Raw264.7 macrophages was 289 
reduced upon hemin treatment with cellular markers suggesting increased levels of M2 290 
macrophage polarisation.  Complementary in vivo investigations showed hemin 291 
administration reduced adipose tissue inflammation in mice fed a HFD for 2 weeks 292 
concomitant with reduced markers of M1 macrophage polarisation (Tu et al., 2014).  A 293 
caveat to this and most other in vivo studies is that induction of HO-1 is typically associated 294 
with a reduction in body weight and/or body weight gain (Cao et al., 2012a; Cao et al., 295 
2012b; Csongradi et al., 2012; Hinds et al., 2014; Li et al., 2008; Ndisang et al., 2014; 296 
Ndisang and Tiwari, 2015; Tu et al., 2014) which would, in-itself, be predicted to decrease 297 
adipose tissue as well as systemic inflammation and to increase adiponectin. 298 
Genetic attempts to increase the activity of HO-1 specifically in adipocytes have also been 299 
performed.  Two independent studies used the aP2 promoter to drive expression of HO-1 in 300 
adipocytes via lentiviral or transgenic approaches.  In the first, intracardial injection of a 301 
lentiviral (aP2-HO-1) construct resulted in increased expression of HO-1 in adipose tissue 302 
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and this was sufficient to attenuate high fat diet (HFD) induced changes in body weight, 303 
associated metabolic sequelae and improved adiponectin (Cao et al., 2012b).  In the second, a 304 
classic transgenic approach was used to increase HO-1 in adipose tissue but, in contrast to the 305 
above report, this failed to ameliorate HFD-induced obesity, insulin resistance or the decrease 306 
in adiponectin (Huang et al., 2013).  The explanation for such contrasting findings remains 307 
obscure but may, at least in part, be explained by the different methodologies employed to 308 
increase HO-1.  It is noteworthy that in both instances expression of HO-1 in cells other than 309 
mature adipocytes is to be expected as the aP2 promoter is switched on early in the 310 
differentiation process, meaning immature adipocytes will also express increased HO-1, and 311 
it also drives gene expression in a range of non-adipocyte cells including cardiomyocytes and 312 
macrophages (Wang et al., 2010).  Consistent with the latter, transgenic overexpression of 313 
HO-1 by aP2 resulted in increased HO-1 in peritoneal macrophages, and, although this was 314 
sufficient to affect the expression of some M2 markers in the adipose tissue of transgenic 315 
mice it was not sufficient to protect against obesity, decreased adiponectin and metabolic 316 
dysfunction (Huang et al., 2013).  Taken together these studies further highlight the 317 
association between reduced body weight and improved adiponectin levels.  318 
Whilst the overwhelming weight of evidence argues in favour of a beneficial effect of HO-1 319 
induction in the context of cardiometabolic disease there remain a number of elements that 320 
demand further exploration.  For example, it is unclear what mechanism(s) underpin any 321 
observed changes in body weight.  Reduced food intake (Galbraith and Kappas, 1989, 1991) 322 
and elevated metabolism, heat production and activity (Csongradi et al., 2012) have been 323 
proposed although, at least in some instances, these changes appear to occur in the presence 324 
of HO-1 inhibition (Choudhary et al., 2013; Ndisang and Tiwari, 2015), arguing against a 325 
central role for HO-1 activity in this context.  However, perhaps the most thought-provoking 326 
and challenging work in this area comes from the recent, elegant and comprehensive report 327 
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from Pospisilik, Esterbauer and colleagues (Jais et al., 2014) which continues to put HO-1 328 
centre-stage of obesity and insulin resistance but as a driver rather than a brake of obesity-329 
associated inflammation.  In keeping with findings from the current study, they found no 330 
evidence of a major role for HO-1 in the adipocyte or muscle or pancreatic β-cells (Jais et al., 331 
2014).  However, they presented compelling data to indicate a predominant role for HO-1 in 332 
both myeloid and hepatic cells that lead them to propose inhibitors, rather than inducers, of 333 
HO-1 may represent effective therapeutic agents (Jais et al., 2014). 334 
In summary, in the current report we demonstrate that induction of HO-1 in human 335 
adipocytes has no direct effect on adiponectin production.  In addition, induction of HO-1 did 336 
not ameliorate the effects of TNFα on adiponectin or pro-inflammatory adipocytokine 337 
production.  These findings argue against a direct HO-1 – adiponectin axis and also suggest 338 
mature adipocytes are unlikely to be acutely involved in mediating the systemic effects of 339 
HO-1 induction. 340 
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6.  Figure Legends 515 
Fig 1. Acute CoPP treatment (24-48 h) induces HO-1 in a dose-dependent manner in 516 
SGBS adipocytes. Fully differentiated SGBS adipocytes were incubated with increasing 517 
concentrations of CoPP (50, 100 and 150 nM) in the absence or presence of TNFα (50 518 
ng/mL) for either 24 or 48 h.  HO-1 mRNA after treatment for (A) 24 or (B) 48 h.  HO-1 519 
protein after treatment for (C) 24 or (D) 48 h.  Values are presented as mean ±SEM of 4 520 
independent experiments and expressed as fold-increase over untreated control. ** = p<0.01, 521 
*** = p<0.001 significant difference compared to control. 522 
Fig 2. CoPP has no effect on adiponectin production in SGBS adipocytes. Fully 523 
differentiated SGBS adipocytes were incubated with increasing concentrations of CoPP (50, 524 
100 and 150 nM) in the absence or the presence of TNFα (50 ng/mL) for either 24 h or 48 h. 525 
Adiponectin mRNA after treatment for 24 h (A) and 48 h (B).  Total adiponectin secretion 526 
after treatment for 24 h (C) and 48 h (D).  HMW adiponectin secretion after treatment for 24 527 
h (E) and 48 h (F). Values are presented as mean ±SEM of 4 independent experiments and 528 
expressed as fold-increase over untreated control. ** = p<0.01, *** = p<0.001 significant 529 
difference compared to non-TNFα treated cells.  Absolute secreted total / HMW adiponectin 530 
concentrations for control cells were: 24 h -  total 173.5 ± 37.6 (99.1 – 263.5) / HMW 69.4 ± 531 
23.7 (27.5 – 137.2): 48 h - total 122.3 ± 43.8 (33.5 – 218.0) /  HMW 55.9 ± 20.8 (12.3 – 532 
106.5) ng/ml. 533 
Fig 3. CoPP does not ameliorate TNFα-stimulated pro-inflammatory cytokine 534 
production in SGBS adipocytes. Fully differentiated SGBS adipocytes were incubated with 535 
increasing concentrations of CoPP (50, 100 and 150 nM) in the absence or presence of TNFα 536 
(50 ng/mL) for either 24 or 48 h.  IL-6 mRNA after (A) 24 h and (B) 48 h. IL-6 secretion 537 
after (C) 24 and (D) 48 h.  TNFα mRNA after (E) 24 h and (F) 48 h.  MCP-1 mRNA after 538 
(G) 24 h and (H) 48 h. Data are presented as mean ±SEM of 4 independent experiments and 539 
expressed as fold-increase over untreated control. **=p<0.01, ***=p<0.001 significant 540 
difference compared to non-TNFα treated cells. 541 
Fig 4. CoPP has no effect on markers of ER stress in SGBS adipocytes. Fully 542 
differentiated SGBS adipocytes were incubated with increasing concentrations of CoPP (50, 543 
100 and 150 nM) in the absence or presence of TNFα (50 ng/mL) for either 24 or 48 h. sXBP-544 
1 mRNA after 24 h (A) and 48 h (B).  BIP mRNA after 24 h (C) and 48 h (D).  CHOP 545 
mRNA after 24 h (E) and 48 h (F). Values are presented as mean ±SEM of 4 independent 546 
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experiments and expressed as fold-increase over untreated control. *** = p<0.001 significant 547 
difference compared to non-TNFα treated cells. 548 
 549 
Fig 5. Induction of HO-1 with hemin has no effect on adiponectin or pro-inflammatory 550 
cytokine production in SGBS adipocytes. Fully differentiated SGBS adipocytes were 551 
incubated with increasing concentrations of hemin (1 and 5 μM) in the absence or presence of 552 
TNFα (50ng/mL) for 48 h.  (A) Cellular HO-1 protein. (B) Secreted total adiponectin. (C) 553 
Secreted IL-6.  Fully differentiated SGBS adipocytes were incubated with hemin (5 M) or 554 
CoPP (150 nM) in the absence or presence of TNFα (50ng/mL) for 48 h. (D) and (E) Cellular 555 
ferritin levels. Data are presented as mean ±SEM of 4 independent experiments and 556 
expressed as fold-increase over untreated control. *=p<0.05, **=p<0.01, ***=p<0.001 557 
significant difference compared to control or non-TNFα treated cells. #=p<0.05 significant 558 
difference compared to TNFα treatment.  Absolute secreted total adiponectin for control cells 559 
was: 577.3 ± 56 (417.9 – 663.6) ng/ml. 560 
Fig 6. Induction of HO-1 with CoPP has no effect on adiponectin or pro-inflammatory 561 
cytokine production in SGBS adipocytes in serum. Mature SGBS adipocytes were 562 
differentiated and maintained in the presence of serum and then incubated with increasing 563 
concentrations of CoPP (5 and 10 μM) in the absence or the presence of TNFα (50 ng/mL) 564 
for 24 h. (A) HO-1 mRNA. (B) Adiponectin mRNA and (C) Adiponectin (total) secretion.  565 
(D) IL-6 mRNA and (E) secretion. Data are presented as mean ±SEM of 4 independent 566 
experiments and expressed as fold-increase over untreated control. *=p<0.05, **=p<0.01, 567 
***=p<0.001 significant difference compared to control or non-TNFα treated cells.  Absolute 568 
secreted total adiponectin for control cells was: 340.8 ± 42.6 (280.6 - 401.1) ng/ml. 569 
Fig 7. Induction of HO-1 with CoPP has no effect on adiponectin or pro-inflammatory 570 
cytokine production in primary human adipocytes. Primary human adipocytes were 571 
differentiated in the absence or presence of serum and then incubated in the same with 572 
increasing concentrations of CoPP (50, 100  and 150 nM in the absence of serum; 5 and 10 573 
μM in the presence of serum) in the absence or the presence of TNFα (50 ng/mL) for 24 h. 574 
HO-1 mRNA in the (A) absence (B) and presence of serum.  Adiponectin mRNA in the (C) 575 
absence and (D) presence of serum.  Secreted total adiponectin in the (E) absence and (F) 576 
presence of serum.  IL-6 mRNA in the (G) absence and (H) presence of serum. Secreted IL-6 577 
in the (I) absence and (J) presence of serum. Data are presented as mean ±SEM of 2 578 
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independent experiments and expressed as fold-increase over untreated control. ***=p<0.001 579 
significant difference compared to control or non-TNFα treated cells.  Absolute secreted total 580 
adiponectin for control cells was: minus serum - 1143.4 ± 16.7 / plus serum - 514.4 ± 14.5 581 
ng/ml 582 
 583 
Highlights 
We report that in mature human adipocytes: 
• Inducers of HO-1 acutely (24-48 h) increase HO-1 mRNA, protein and activity  
• Acute induction of HO-1 does not enhance or rescue adiponectin production in healthy or TNFα-
treated cells 
• Acute induction of HO-1 does not ameliorate TNFα-stimulated expression and secretion of pro-
inflammatory adipocytokines 
  
*Highlights (for review)
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